PUBLISHER: The Business Research Company | PRODUCT CODE: 1810826
PUBLISHER: The Business Research Company | PRODUCT CODE: 1810826
Anti-D immunoglobulin is a specialized blood product derived from human plasma that contains antibodies targeting the RhD antigen present on red blood cells. It is produced by collecting plasma from donors sensitized to the RhD antigen, followed by purification and concentration of the specific immunoglobulin G (IgG) antibodies.
The primary product types of anti-D immunoglobulin include intramuscular and intravenous formulations. Intramuscular anti-D immunoglobulin is a plasma-derived antibody preparation administered into muscle tissue to prevent Rh incompatibility in Rh-negative individuals by neutralizing Rh-positive fetal red blood cells. These products are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used for applications including hemolytic disease of the newborn, immune thrombocytopenic purpura, antenatal and postnatal prophylaxis, among others. They serve several end users, including hospitals, clinics, blood banks, and research laboratories.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The anti-D immunoglobulin market research report is one of a series of new reports from The Business Research Company that provides anti-D immunoglobulin market statistics, including anti-D immunoglobulin industry global market size, regional shares, competitors with a anti-D immunoglobulin market share, detailed anti-D immunoglobulin market segments, market trends and opportunities, and any further data you may need to thrive in the anti-D immunoglobulin industry. This anti-D immunoglobulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anti-D immunoglobulin market size has grown strongly in recent years. It will grow from $2.42 billion in 2024 to $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth observed during the historic period can be attributed to increasing awareness of rhesus incompatibility risks, the expansion of national immunization programs, implementation of maternal and neonatal health policies, rising global birth rates, and growth in blood transfusion procedures.
The anti-D immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to rising demand for antenatal and perinatal care, increased focus on maternal health in low- and middle-income countries, growing investments in healthcare infrastructure, expansion of universal health coverage programs, and regulatory support for immunoglobulin therapies. Major trends expected in this period include advancements in plasma fractionation technology, development of recombinant antibody alternatives, increased automation in immunoglobulin production, adoption of high-purity formulation techniques, and integration of cold chain monitoring systems.
The increasing global birth rates are expected to drive the growth of the anti-D immunoglobulin market in the future. Birth rates measure the number of live births per 1,000 people annually in a population. These rates are rising due to limited access to education and family planning services, leading to higher fertility rates and larger families. Anti-D immunoglobulin supports these birth rates by preventing Rh incompatibility during pregnancy, which lowers the risk of hemolytic disease in newborns and promotes healthier outcomes in subsequent pregnancies. For example, in April 2025, the Centers for Disease Control and Prevention, a US government agency, reported 3,622,673 births in 2024, marking a 1% increase compared to the previous year. Thus, the rising birth rates are fueling the expansion of the anti-D immunoglobulin market.
The growth of healthcare infrastructure is also expected to boost the anti-D immunoglobulin market going forward. Healthcare infrastructure encompasses the facilities, equipment, workforce, and support systems necessary to provide medical services to a population. The expansion of healthcare infrastructure is driven by the growing global population, which increases the demand for healthcare and necessitates the development of additional hospitals, clinics, and resources. Improved healthcare infrastructure enhances access to maternal care, facilitating better screening and timely administration of anti-D immunoglobulin to prevent hemolytic disease in newborns. For instance, in May 2023, the Department of Health and Social Care, a UK government department, announced plans to invest over $27 billion (£20 billion) in constructing new hospital facilities. Under the New Hospital Programme, two hospitals have been completed, five are under construction, and more than 20 are planned or in progress to be finished by the end of the following year. Therefore, the expanding healthcare infrastructure is contributing to the growth of the anti-D immunoglobulin market.
Leading companies in the anti-D immunoglobulin market are concentrating on innovative developments such as recombinant anti-D immunoglobulin to increase access to safe and reliable prophylaxis for Rh-negative pregnant individuals and enhance maternal health outcomes. Recombinant anti-D immunoglobulin is a laboratory-engineered monoclonal antibody designed to prevent Rh incompatibility in Rh-negative patients, providing an alternative to plasma-derived anti-D treatments with improved consistency, safety, and scalability. For example, in January 2022, Bharat Serums and Vaccines (BSV), an India-based biopharmaceutical company, launched the world's first marketed recombinant anti-Rho (D) immunoglobulin. This product offers a scientifically advanced approach to Rh prophylaxis by using recombinant technology, which improves product reliability and reduces variability seen in plasma-derived options. Its availability is especially important in regions with a high prevalence of Rh-negative pregnancies, where it can enhance preventive care and lower the risk of hemolytic disease in newborns.
Major players in the anti-d immunoglobulin market are Merck Group, Bayer AG, CSL Behring, Baxter International Inc., Intas Pharmaceuticals Ltd., Octapharma AG, Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kedrion Biopharma Inc., Biotest AG, Sanquin, Taj Pharmaceuticals Limited, Kamada Pharmaceuticals, Bharat Serums and Vaccines Limited, Saol Therapeutics Inc., Aetos Pharma Private Limited, Avin Darou, PV Pharma Healthcare Pvt. Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Ocean Pharmacoat Pvt. Ltd.
North America was the largest region in the anti-D immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-D immunoglobulin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anti-D immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The anti-D immunoglobulin market consists of sales of hepatitis B immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, and varicella-zoster immunoglobulin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Anti-D Immunoglobulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on anti-d immunoglobulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for anti-d immunoglobulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-d immunoglobulin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.